J Malaise, A De Roover, J P Squifflet, W Land, P Neuhaus, J Pratschke, A Kahl, A Pascher, S Boas-Knoop, H Arbogast, J Hoffmann, W D Illner, Seissler, Schlamp, Viebahn, Wunsch, Hajt, E Klar, W Scharek, Hopt, P Pisarski, O Drognitz, C Thurow, K Dette, W O Bechstein, G Woeste, J Klempnauer, T Becker, Lück, Neipp, A Königsrainer, W Steurer, R Margreiter, Mark, Bonatti, F Saudek, P Boucek, M Adamec, T Havrdova, R Koznarova, Y Vanrenterghem, J Pirenne, B Maes, D Kuypers, W Coosemans, P Evenepoel, D van Ophem, V Marcelis, van Vlem, Peeters, de Hemptinne, de Roose, L Fernandez-Cruz, M J Ricart, R Nakache, P Morel, T Berney, S Demuylder
The Immunosuppression in Pancreas Transplantation was historically based on the fact that the pancreas is an extremely immunogenic organ. Quadruple drug therapy with polyclonal or monoclonal antibodies induction was the mainstay therapy since the introduction of Cyclosporine A. In the modern era of Immunosuppression, Mycophenolate Mofetil replaced Azathioprine while Tacrolimus-another potent calcineurin inhibitor-had-and still has-a difficult challenge to replaced Cyclosporine A, due to its potential diabetogenic effect...
November 2008: Acta Chirurgica Belgica